Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

Robbins LLP is soliciting UNCY stockholders to seek lead-plaintiff status in a securities class action covering purchases between December 29, 2025 and June 29, 2026, with a November 2, 2026 deadline. The complaint alleges Unicycive failed to disclose that it had not inspected or audited its third-party manufacturing vendor's facility, and the FDA's June 2026 CRL on the resubmitted OLC NDA cited the same vendor deficiencies as the June 2025 CRL.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.